Streetbeat News

NRXP

NRx Pharmaceuticals, Inc.

https://www.nrxpharma.com

Industry

Biotechnology

NRX Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, develops novel therapeutics for the treatment of central nervous system disorders and life-threatening pulmonary diseases. Its products include ZYESAMI, an investigational drug that has completed a Phase IIb/III clinical study for COVID-19 related respiratory failure; and NRX-100 and NRX-101 oral therapeutics for the treatment of bipolar depression in patients with acute suicidal behavior/ideation and sub-acute suicidal ideation and behavior. The company was founded in 2015 and is based in Wilmington, Delaware.

Open

1.30

Mkt cap

14M

Volume

128K

High

1.33

P/E Ratio

-0.49

52-wk high

7.33

Low

1.28

Div yield

N/A

52-wk low

1.10

NRx Pharmaceuticals has entered into an agreement with LifeSci Associates, under which LifeSci will provide financial services and support to NRx.

Portfolio Pulse from Benzinga Newsdesk

September 14, 2023 | 8:02 pm

During Friday's after-market session, several health care stocks experienced significant movement. Cingulate (CING), Clene (CLNN), Elutia (ELUT), Etao International Co (ETAO), Atossa Therapeutics (ATOS), and Renalytix (RNLX) saw their stocks rise, with Cingulate leading the gainers with a 19.4% increase. On the other hand, Tenon Medical (TNON), Axcella Health (AXLA), Alzamend Neuro (ALZN), NRX Pharmaceuticals (NRXP), Trevena (TRVN), and Inspire Veterinary (IVP) saw their stocks fall, with Tenon Medical leading the losers with a 30.3% decrease.

Portfolio Pulse from Benzinga Insights

September 08, 2023 | 9:31 pm

NRx Pharmaceuticals has submitted an investigational new drug application to the FDA for NRX-101, a drug intended for chronic pain treatment.

Portfolio Pulse from Benzinga Newsdesk

August 30, 2023 | 10:49 am

NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) has entered into a definitive purchase agreement with accredited investors to sell 3,000,000 shares of preferred stock at $0.40 per share. These shares will convert into common shares and warrants to purchase common stock at the same price after six months.

Portfolio Pulse from Benzinga Newsdesk

August 29, 2023 | 10:56 am

During Thursday's intraday session, several healthcare stocks experienced significant movements. Gainers included Nemaura Medical (NMRD), NRX Pharmaceuticals (NRXP), Bionomics (BNOX), Modular Medical (MODD), Impel Pharmaceuticals (IMPL), and Werewolf Therapeutics (HOWL). Losers included Longeveron Inc. - Subscription Right (LGVNR), Societal CDMO (SCTL), Aravive (ARAV), GRI Bio (GRI), T2 Biosystems (TTOO), and RVL Pharmaceuticals (RVLP).

Portfolio Pulse from Benzinga Insights

August 24, 2023 | 5:31 pm

Jonathan C Javitt, a director at NRX Pharmaceuticals, has purchased 100,000 shares of the company's stock at a price of $0.33 per share, according to a Form 4 filing with the SEC.

Portfolio Pulse from Happy Mohamed

August 24, 2023 | 4:27 pm

In Friday's pre-market session, several healthcare stocks saw significant movement. Alpha Tau Medical, NeuBase Therapeutics, Avalo Therapeutics, Timber Pharmaceuticals, AcelRx Pharmaceuticals, and TRACON Pharma all saw increases in their share prices. Conversely, Athersys, CervoMed, Bone Biologics, Scilex Holding, Predictive Oncology, and NRX Pharmaceuticals all experienced decreases.

Portfolio Pulse from Benzinga Insights

August 18, 2023 | 1:06 pm

NRX Pharmaceuticals reported Q2 losses of $(0.12) per share, beating the analyst consensus estimate of $(0.14) by 14.29%. However, this represents a 9.09% increase in losses compared to the same period last year.

Portfolio Pulse from mahesh@benzinga.com

August 14, 2023 | 8:46 pm

NRX Pharmaceuticals (NASDAQ:NRXP) is set to release its latest quarterly earnings report on Monday, 2023-08-14. Analysts estimate an earnings per share (EPS) of $-0.14. The company's past performance shows a pattern of EPS misses followed by share price increases. The stock is currently trading at $0.31, down 58.05% over the last 52-week period.

Portfolio Pulse from Benzinga Insights

August 11, 2023 | 2:01 pm

On Wednesday, 155 companies set new 52-week lows. The largest company by market cap to set a new 52-week low was Estee Lauder Cos (NYSE:EL). The smallest company by market cap to set a new 52-week low was SenesTech (NASDAQ:SNES). Siyata Mobile (NASDAQ:SYTA)'s stock fell the most, as it traded down 7658.62% to reach a new 52-week low. Sutro Biopharma (NASDAQ:STRO) was the biggest winner of the bunch, with shares actually trading up 0.0% after it rebounded from its new 52-week low.

Portfolio Pulse from Benzinga Insights

August 09, 2023 | 4:27 pm

All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.